Four Houston accelerators will be working together this summer to advance nearly 30 university-associated startups. Photo via UH.edu

The University of Houston and Rice University have announced the cohorts for their summer accelerators that advance university-founded startups and small businesses.

The two schools run four programs in tandem with each other every summer for about a decade. There are nearly 30 companies this year being accelerated across the four programs, which are:

  • Rice's OwlSpark is focused on early-stage startup teams.
  • UH's RED Labs is focused on early-stage startup teams.
  • Rice's BlueLaunch is focused on non-tech small businesses.
  • UH's RED Launch is focused on non-tech small businesses.

"A very cool part of the program is that we partner every summer with Rice University's OwlSpark and Blue Launch," says Liana Gonzalez-Schulenberg, managing director of RED Labs. "It creates this really incredible network across the universities and allows both schools to bolster and benefit from each other.

"We share staff, we share mentors, we share speakers, we co-host the demo day, and we even share the catering bill," she continues. "It's a really special part of the program that I think has brought endless value to the founders, the universities, and Houston."

The 12-week program takes each of the teams — all of which have a university-affiliated founder, from undergrad to faculty — through key programming and mentorship. The final event includes a pitch day, called the Bayou Startup Showcase, where all of the companies share their business plans they've created through the program.

“I’m excited to support these new ventures with highly curated offerings and rich mentorship, propelling them to commercial success,” said Jessica Fleenor, managing director of BlueLaunch and OwlSpark. "We have built a long-standing culture of advocacy and collaboration, and look forward to upholding that in our largest cohort to date."

The selected companies for the four programs are as follows.

RED Labs (cohort 11)

  • We Felt It 3-D prints customized modifications to mobility devices like canes, walkers, and wheelchairs that maximizes comfort during use.
  • Zoop makes nutrition easy, clean and sustainable smoothie premixes which can be consumed anywhere and anytime by just mixing it with any of the preferred mixer (Water, Vegan milk, Milk, etc.)
  • Orbit is an application that allows users to understand the stock market through practice and training.
  • Team X is creating a company around nanoporous membrane technologies that recovers metals from wastewater and brine.

OwlSpark (cohort 11)

  • Terradote will manufacture cost-competitive, petroleum-free chemicals using captured carbon dioxide, methane and renewable bio-based materials.
  • Biomethanator’s biofilm bioreactors utilize biomethanation to convert industrial-waste carbon dioxide to methane, which can be used as fuel or in other industrial applications.
  • TaurusVascular is developing a minimally invasive catheter for addressing the most pressing complication of endovascular aortic aneurysm repair: endoleaks.
  • Voythos offers a mobile physician companion that monitors electronic medical records, prompting action and initiating care workflows.
  • AiKYNETIX is developing a video analytics platform for human motion insights, focusing on a mobile running lab for runners and coaches.
  • AllStars is building an affect-sensitive educational tool for self-studying and blended classroom learning.
  • EurekaHub is developing a marketplace where data and research scientists can publish, manage, share and revise analytical models for data sets across diverse applications.
  • ScoutBetter is an end-to-end recruiting platform that connects students with corporate campuses and provides recruiters access to university talent.

RED Launch (cohort 2)

  • CurioSweets is a vegan dessert brand that provides wholesale desserts and services including: consultation; recipe development; and contract baking of their product.
  • SpaceCityVinyl is a vehicle wrapping business that offers a quick and non permanent color change of vehicles.
  • Venus by Design is a handmade jewelry company
  • First Byte Digital consulting firm that helps mom and pop restaurants and non-profits establish a robust online presence by offering a wide range of digital conversion services.
  • 2tinys designs, prints, and cuts stickers with the plan of expanding into art prints and stationery items.
  • Lacey's Art paints dog portrait artwork. They partner with shelters to find models (and provide some help to getting the dog adopted), and then sells the prints.

BlueLaunch (cohort 2)

  • Archway Family Medicine provides medical care to patients through a monthly membership model known as direct primary care.
  • rdy helps communities recover from disasters faster and more equitably by working with local organizations to plan for them.
  • 610Smokehouse is a mobile food service and catering company that serves “Texan Fusion,” a unique cuisine that combines traditional Texas barbecue with diverse Houston food.
  • SerendipityPicnic is a unique picnic with all the goodies and essentials wrapped in a beautiful, lightweight, easy-to-carry and reusable “BlanKIT.”
  • La Mer Macaron offers an assortment of homemade French macarons.
  • TenTwelve provides residential construction and remodeling services.
  • DHA America customizes, designs and sells powder-coated and galvanized fence panels, posts and accessories.
  • All About Baby provides bespoke tableware for babies transitioning to solid foods.
  • MeowPlanet is opening a cat lounge.

Eight of the 10 most-promising life science startups named at BioHouston and the Rice Alliance's event are based in Houston. Photo courtesy of Rice Alliance

Houston startups named most promising in the life science space at annual event

ones to watch

For the second time this year, Houston life science leaders and startup founders gathered to discuss the future of health care in Houston.

The annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship was usually held during the fall before the pandemic pushed it off schedule. In February, the two organizations hosted the previous forum, but as of this month, the annual event is back on track.

The day included panels and networking, plus over 50 companies — about half of which are based in Houston — pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Houston-based Bairitone Health won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The company is creating a wearable technology that takes a more innovative approach to sleep apnea and snoring with its SOMNAR platform that detects tissue-born sounds, identifies obstructions, and more. The award was presented by Ann Tanabe, CEO of BioHouston.

Ann Tanabe, CEO of BioHouston, presented the DeBakey Award to Houston-based Bairitone Health. Photo courtesy of Rice Alliance

For the first time, the event also named a people's choice award winner, as voted on by the audience members. Baritone Health also claimed the prize.

At the conclusion of the event, the Rice Alliance and BioHouston named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Autonomize

Austin-based Autonomizeunlocks data and context to enable human health outcomes

bEHR Health Systems

New Orleans-based bEHR Health Systemsdelivers, medical, lifestyle, and social solutions to health for African Americans.

EMPIRI

EMPIRI, based in Houston, is revolutionizing cancer care with a novel technology that accurately predicts each cancer patient's treatment responses empirically, enabling doctors to make the optimal treatment selection for each cancer patient.

InformAI

Houston-based InformAI develops AI-based medical image diagnostic tools and uses large dataset synthesis to develop clinical outcome predictors for physicians, hospitals, and medical imaging/medical device companies

March Biosciences 

Houston-based March Biosciences is impacting the most challenging lymphoma and leukemia.

MRG Health-SmartCare360

MRG Health-SmartCare360, based in Houston, is a determinate of health and disease specific virtual care management technology and services company that improves patient access to care and clinical outcomes for people suffering from one or more chronic disease.

Prana Thoracic

Prana Thoracic, founded in Houston out of JLABS at TMC, is a medical device startup that's innovating for the future of early intervention in lung cancer.

Steradian Technologies

Another med device startup based in Houston,Steradian Technologiesemploys deep-photonics technology to diagnose respiratory diseases in seconds, all for the price of a latte.

TYBR Health

Houston-based TYBR Health makes a hydrogel that protects tendons from scarring after surgery and improves patient outcomes.

Voythos

Voythos, based in Houston, is making medical records work for today's healthcare.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice researchers score $45M from NIH for cancer-fighting tech

freshly funded

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

TMC again expands global impact with new Netherlands partnership

breaking news

The Texas Medical Center may be based in Houston, but the organization has again grown its global impact.

Since 2016, TMC’s BioBridges have worked with 88 startup companies. Those include strategic alliances with four other countries. Australia, the United Kingdom, Denmark and Ireland are all among TMC’s BioBridges partners. As of today, add the Netherlands to that list.

On September 27, TMC president and CEO, William F. McKeon, and Carmen van Vilsteren, chair of Health~Holland, Top Sector Life Sciences & Health (LSH), signed an agreement in Rotterdam. The TMC Netherlands BioBridge Memorandum of Understanding codifies the innovative goals of the partnership. Essentially, the BioBridge program provides a means for entrepreneurs, researchers, clinicians and industry partners from other countries to access the US market, as well as TMC experts.

“The TMC Netherlands BioBridge represents an unparalleled opportunity for collaboration and growth,” Ashley McPhail, chief external affairs & administration officer at Texas Medical Center said in a press release. “The Netherlands has solidified its position as a global leader in the field of life sciences and health, with a thriving ecosystem of research institutions, innovative companies, and highly skilled professionals. This strategic partnership will bring positive benefits to patients, clinicians and industry partners on a global scale.”

This lifeline for international healthcare companies makes expansion into the United States far smoother. The Global Innovators Launch Pad allows for startup founders to take part in a 10-week residency at the TMC Innovation Factory that will teach them about foundational infrastructure, clinical evidence and funding in the US.

“Since Texas is an important hub for innovation in the MedTech and digital health sectors, the collaboration with Texas Medical Center creates opportunities for Dutch companies looking to expand their international reach. Vice versa, it gives companies in Texas access to the vibrant Dutch Life Sciences & Health sector,” said van Vilsteren.

That exchange includes members of the TMC gaining the opportunity to participate in the Health~Holland Visitors Programme (HVP), “Shaping the Healthcare of the Future.”

The annual event invites high-level representatives from the private sector, NGOs, knowledge institutions, healthcare providers and different tiers of government to share their expertise.

It's the fifth partnership of its kind for TMC, with the last one being with Ireland, announced last year. TMC's other global initiatives include accelerators with Denmark and the United Kingdom, both announced earlier this year.

Houston startup founders prepare to scale globally following Shark Tank success

HOUSTON INNOVATORS PODCAST EPISODE 205

While Milkify's founders — husband and wife team Pedro Silva and Berkley Luck — secured partners on a popular business pitch and investment show, the entire experience almost didn't happen.

Silva and Luck, who got her PhD in molecular and biomedical s at Baylor College of Medicine, founded the company to provide breast milk freeze drying as a service to Houston-area families. Now, Milkify has customers across the country, but the duo didn't know if going through the process would be worth the investment and publicity, or if it would just be a distraction.

"The competitor in me wanted to be the first breast milk company to go on the show and to tell our story to the world — to show the world what my wife came up with that we thought was so great," Silva says on the Houston Innovators Podcast. "It was probably the scariest 45 minutes of my life."

But the sharks bit. Milkify's episode aired in April, and two investors — Gwyneth Paltrow and Lori Greiner — agreed to a $400,000 convertible note for 20 percent equity in the company. Paltrow even said on the show that she would have used the service when she was breastfeeding.

"It was empowering," Luck says of getting to wear her white coat on TV and share the story of how she came up with the idea of Milkify. "It was important to me when we went on the show to express that this had a scientific basis, that we didn't start this lightly, and that we've made huge strides in doing this in the absolute safest way possible."

Silva says they can't talk about some of the details of the show or the deal, but since then, Milkify has reached new customers, received additional investment interest, grown its team, and built out its plan to scale, the founders shared on the podcast. The team also shares its big-picture scale plans, which include tapping international partners to potentially take Milkify's tech global.

"Our vision is for every family to have access to breast milk formula, but instead of re-creating breast milk in a lab, we're doing it with mom's own milk," Silva says, mentioning a partnership with a breast milk bank that will convert its operation from freezing to freeze drying donated milk. "We're also working with groups in the UK and Australia to launch similar services using our patented technology."

"By the end of the year, we hope to see some announcements with those partnerships across the globe."

From the beginning, the importance of Milkify's team has been on supporting working parents to give them the best way to care for their families, Silva says. And for Luck — who says she's proud of the integrity Milkify has at its core despite competitors offering lower-quality and, in some cases, dangerous alternatives — she sees a lot of research benefits for the company.

"It's amazing to be at this leading edge, not just of innovation but of research, and to be able to still put out meaningful advances as an industry partner, not just as an academic," Luck says, adding that she hopes to be able to continue to contribute to the ongoing research into breast milk.

Luck and Silva share more about their Shark Tank experience, their co-founder strengths, and the future of Milkify on the podcast. Listen to the interview here — or wherever you stream your podcasts — and subscribe for weekly episodes.